DCM
BCYC

Difesa Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Difesa Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,500
Closed -$213K – 253
2021
Q4 		$213K Buy
+3,500
New +$193K 0.14% 110

Other funds holding BCYC

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Difesa Capital Management's BCYC Position: Q1 2022 in Review

Difesa Capital Management sold out of Bicycle Therapeutics (BCYC) in Q1 2022, closing a stake of 3,500 shares — an estimated $213K sold.

Difesa Capital Management first reported a position in BCYC in Q4 2021 and held it in 1 quarter. The position peaked at $213K in Q4 2021. 105 funds tracked by Wall St. Rank hold BCYC as of Q1 2022.

  • Difesa Capital Management reported no remaining Bicycle Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Difesa Capital Management sold 3,500 Bicycle Therapeutics shares in Q1 2022, an estimated $213K.
  • Difesa Capital Management first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 1 quarter.
  • Difesa Capital Management's Bicycle Therapeutics position peaked at $213K in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2022.

Based on Difesa Capital Management's 13F filing for Q1 2022, filed 16 May 2022.